Amgen’s (AMGN) Neupogen currently accounts for 76% of the neutropenia market in the United States. Amgen expects that the drug will lose market share in 2016. In 2015, Neupogen lost about 3% market ...
Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym. Nivestym has been approved ...
WASHINGTON (Reuters) - U.S. drug regulators gave the nod to a Teva Pharmaceutical Industries drug that boosts the production of infection-fighting white blood cells in certain cancer patients ...
(Reuters) - A panel to the U.S. Food and Drug Administration unanimously backed the approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, setting the stage for the ...
NEW YORK, NY / ACCESSWIRE / March 2, 2016 / A new cell therapy can heal radiation damage and save lives following a dirty bomb detonation, nuclear attack, or nuclear power plant accident. In ...
March 16, 2005 — The U.S. Food and Drug Administration (FDA) approved in December 2004 revisions to safety labeling to advise healthcare professionals of the following changes: use of interferon ...
A biosimilar version of filgrastim (EP2006, Sandoz/Novartis) has today been recommended for approval in the United States. The new product is like a generic version of the brand-name filgrastim, ...
An Indiana University Melvin and Bren Simon Cancer Center researcher played a role in the recent Food and Drug Administration approval of a drug to treat people exposed to potentially lethal doses of ...
The first wave of biosimilars began lapping at U.S. shores five years ago when the FDA approved Sandoz Inc.’s Zarxio on March 6, 2015, giving it a label identical to that of its reference biologic, ...
That's because, unlike standard generics, Teva's tbo-filgrastim can't simply be substituted for Neupogen. Doctors will have to prescribe it by name, just as they do branded drugs. And that means Teva ...
Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym. Nivestym has been approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results